385908

Hyaluronic Acid, Sodium Salt, Streptococcus pyrogenes

Natural high-viscosity mucopolysaccharide with alternating β1,3-glucuronidic and β1,4-glucosaminidic bonds. Principal glycosaminoglycan in connective tissue fluids.

• Synonim(y): Hyaluronic Acid, Sodium Salt, Streptococcus pyrogenes
• Numer CAS: 9067-32-7
• MDL number: MFCD01773053
• UNSPSC Code: 12352201
• NACRES: NA.79
• Form: lyophilized
• Storage condition: OK to freeze, desiccated (hygroscopic)

Właściwości

• description: Merck USA index - 14, 4757
• Quality Segment: 100
• form: lyophilized
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze, desiccated (hygroscopic)
• impurities: ≤0.070 EU/mg endotoxins (EU/mg NaHy), ≤0.1% protein
• solubility: water: 10 mg/mL
• shipped in: ambient
• storage temp.: 2-8°C
• SMILES string: [Na+].N([C@H]1[C@@H](O[C@@H]([C@H]([C@@H]1O[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O)O)O)C(=O)O)O)CO)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H]([C@@H](O[C@@H]([C@H]3O)CO)O)NC(=O)C)C(=O)O)C(=O)C
• InChI: 1S/C28H44N2O23.Na/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43;/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45);/q;+1/t7-,8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19-,20+,21+,22+,25-,26+,27-,28-;/m1./s1
• InChI key: YWIVKILSMZOHHF-QJZPQSOGSA-N

Opis

General description

Natural high-viscosity mucopolysaccharide with alternating β1,3-glucuronidic and β1,4-glucosaminidic bonds. Principal glycosaminoglycan in connective tissue fluids. The molecular weight of Hyaluronic Acid, Sodium Salt, is in the range of 5.0 x 10⁵ - 1.2 x 10⁶, as calculated from its limiting viscosity.

Application

• Hyaluronic Acid as a LYVE-1 Receptor Ligand in the Lymphatic System of Healthy Human Skin.: This study investigates the role of hyaluronic acid as a ligand for the LYVE-1 receptor in the lymphatic system, offering insights into its physiological roles and potential therapeutic applications, particularly in treating lymphatic-related diseases (Michurina et al., 2024).


• M2 Macrophage-Derived Extracellular Vesicles Encapsulated in Hyaluronic Acid Alleviate Osteoarthritis by Modulating Macrophage Polarization.: This research explores the therapeutic potential of M2 macrophage-derived extracellular vesicles encapsulated in hyaluronic acid for osteoarthritis treatment. It highlights a novel anti-inflammatory mechanism that could be significant for biochemists studying cellular therapies (Yuan et al., 2024).


• Insights into Translational and Biomedical Applications of Hydrogels as Versatile Drug Delivery Systems.: This review covers the use of hyaluronic acid in hydrogel drug delivery systems, emphasizing its utility in various biomedical applications. It provides a detailed analysis of the material′s properties, applications, and future potential in drug delivery and tissue engineering (Kohar et al., 2024).


• Utilizing Ni(II) complex for metal drug-gel particles in cervical cancer treatment and designing novel drugs through machine learning methods.: Although primarily focused on Ni(II) complex, this study discusses the integration of metal drug-gel particles with hyaluronic acid, offering insights into its potential as a carrier for targeted therapy in cervical cancer (Jiang et al., 2024).

Preparation Note

Following reconstitution, refrigerate (4°C). Stock solutions are stable for up to 3 months at 4°C in the absence of contamination.

Heating slowly to 50°C may be required for complete solubilization.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 2
• flash_point_f: Not applicable
• flash_point_c: Not applicable